In recent years, immune checkpoint inhibitors targeting PD-1 and PD-L1 have been widely used in the treatment of various solid tumors including breast cancer, especially TNBC, which is a breakthrough in the field of cancer therapy. Here, CD274 is linked to breast carcinoma.